53.78 0.00 (0.00%)
After hours: 4:48PM EST
|Bid||18.44 x 100|
|Ask||62.62 x 100|
|Day's Range||53.54 - 55.10|
|52 Week Range||45.31 - 71.32|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.38|
Seattle Genetics, Inc. today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc.
Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
MADRID , Feb. 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics ...
Stock Monitor: Seattle Genetics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 12, 2018 / Active-Investors.com has just released a free research report on Pieris Pharmaceuticals, Inc. (NASDAQ: ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, ...
Pieris Pharmaceuticals, Inc. , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, and Seattle Genetics, Inc.
Seattle Genetics, Inc. today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc., has commenced its previously announced tender offer for all outstanding shares of common stock of Cascadian Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Array BioPharma has been on fire all week after announcing encouraging data results and strong earnings for its second quarter. Shares of Seattle Genetics ...
The Bothell, Washington-based company said it had a loss of 41 cents per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research ...
Seattle Genetics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2017. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, enfortumab vedotin and tisotumab vedotin clinical activities, as well as progress with its pipeline of targeted therapies for cancer.
NEW YORK, NY / ACCESSWIRE / February 6, 2018 / Seattle Genetics, Inc. (NASDAQ: SGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 6, 2018 at 4:30 PM Eastern ...
Seattle Genetics (SGEN) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Seattle Genetics, Inc. today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle Genetics’ common stock.
NEW YORK, NY / ACCESSWIRE / February 2, 2018 / Rising bond yields created mixed results on Wall Street Thursday. The S&P 500 Index declined 0.06 percent to close at 2,821.98, while the Nasdaq Composite ...
Stock Monitor: Cascadian Therapeutics Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 02, 2018 / Active-Investors.com has just released a free research report on Seattle Genetics, Inc. (NASDAQ: ...
Intercept, Seattle Genetics and Corcept rose above the froth Thursday — popping on key drug, merger and earnings news.
Cascadian Therapeutics, Inc. (NASDAQ:CASC) is the big mid-week winner its acquisition by Seattle Genetics, Inc. (NASDAQ:SGEN). On Wednesday, January 31st, Cascadian announced that it will be acquired by Seattle Genetics. The deal will see the latter pick up the former at $10 a share, valuing Cascadian at just shy of $614 million based on current […] The post Cascadian Therapeutics Scores Big On Seattle Genetics Acquisition appeared first on Market Exclusive.
While companies like AbbVie (ABBV) were in focus on 4Q earnings results, Ablynx was in the news with the company agreeing to be acquired by French pharma giant, Sanofi.
Seattle Genetics, Inc. today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.00 per share.